US · NTHI
Neonc Technologies Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Calabasas, CA 90069
- Website
- neonctech.com
Price · as of 2024-12-31
$4.06
Market cap 198.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | $0.00 | $0.00 | |||
| 2024 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Neonc Technologies Holdings, Inc.'s (NTHI) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.06
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NTHI | Neonc Technologies Holdin… | $4.06 | 198.27M | — | — | — | — | — | — | — | — | — | — | 100.00% | -8605.45% | -14335.50% | 122.08% | 110.23% | -508.20% | 0.00 | -2.64 | 0.25 | 0.02 | 0.00 | -2125.00% | 1779.00% | 12414.00% | — | -0.47 | 65.03% | — | 0.00% | — | — | — | — | — |
| CDXS | Codexis, Inc. | $2.15 | 172.62M | +1,080% | -47% | — | +173% | -3.17 | 3.09 | 3.49 | -3.31 | — | 3.21 | 72.55% | -98.61% | -109.99% | -85.03% | -128.77% | -45.72% | 0.89 | — | 4.18 | 3.90 | -0.69 | -2054.00% | -1539.00% | -586.00% | -25.95% | -2.09 | -118.20% | 0.00% | 0.00% | 0.00% | -3.31 | -3.60 | 3.26 | -4.07 |
| GNFT | Genfit S.A. | $3.89 | 193.71M | +1,570% | -38% | -54% | +23% | 103.96 | 2.26 | 2.34 | 16.42 | — | 7.38 | 99.55% | 4.90% | 2.25% | 2.20% | 4.87% | 0.93% | 0.90 | 0.69 | 1.23 | 1.19 | -2.36 | -10517.00% | 13456.00% | -12455.00% | 9.08% | 0.20 | 25.88% | 0.00% | 0.00% | 7.69% | 41.76 | 9.63 | 2.04 | -1.81 |
| IVA | Inventiva S.A. | $4.10 | 213.13M | +611% | -70% | — | +3,663% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| IVVD | Invivyd, Inc. | $1.52 | 182.32M | — | — | — | — | -0.70 | 1.77 | 4.72 | -0.30 | — | 1.77 | 93.63% | -696.80% | -669.42% | -138.71% | 1644.29% | -94.75% | 0.02 | — | 1.62 | 1.30 | 0.39 | -2099.00% | — | -181.00% | -142.50% | -2.75 | 1586.23% | 0.00% | 0.00% | 0.00% | -0.29 | -0.30 | 2.04 | -12.54 |
| MDWD | MediWound Ltd. | $18.15 | 197.42M | +13% | -60% | — | — | -5.58 | 5.41 | 8.34 | -4.71 | -1.84 | 5.43 | 8.81% | -95.85% | -149.46% | -96.33% | 446.97% | -43.19% | 0.22 | -34.55 | 1.97 | 1.85 | 0.08 | 30400.00% | 822.00% | 1753.00% | -11.80% | -0.51 | 458.83% | 0.00% | 0.00% | 0.00% | -6.83 | -6.65 | 6.55 | -1.69 |
| OABI | OmniAb, Inc. | $1.43 | 174.93M | +19,739% | +24% | — | +482% | -5.61 | 1.21 | 13.19 | -6.12 | -28.61 | 5.31 | 100.00% | -282.30% | -235.05% | -20.60% | -25.66% | -17.70% | 0.08 | — | 4.52 | 4.29 | 0.09 | 1961.00% | -2275.00% | -600882.00% | -11.94% | -2.63 | -16.47% | 0.00% | 0.00% | 3.92% | -4.18 | -7.51 | 11.81 | 4.59 |
| OBIO | Orchestra BioMed Holdings… | $3.92 | 211.5M | +476% | -57% | — | — | -2.55 | 4.73 | 59.04 | -1.65 | -20.99 | 4.73 | 92.27% | -2437.49% | -2313.27% | -120.84% | 365.45% | -71.21% | 0.50 | — | 4.27 | 4.13 | 0.09 | 1216.00% | -442.00% | 1005.00% | -32.65% | -3.12 | 288.99% | 0.00% | 0.00% | 0.00% | -1.64 | -2.07 | 39.98 | -5.45 |
| SLS | SELLAS Life Sciences Grou… | $1.68 | 177.08M | — | — | — | — | -2.36 | 7.69 | — | 94.85 | — | 9.65 | 0.00% | — | — | -4147.88% | 484.07% | -240.78% | 0.11 | — | 1.72 | 1.46 | -20.39 | -6269.00% | — | -409.00% | -48.61% | -3.72 | 543.81% | 0.00% | 0.00% | 15.46% | -1.90 | -1.69 | — | -18.42 |
| TARA | Protara Therapeutics, Inc… | $4.44 | 171.3M | — | — | — | — | -1.86 | 0.50 | — | 1.70 | — | 0.51 | 0.00% | — | — | -37.88% | -1031.24% | -34.25% | 0.03 | — | 15.71 | 15.54 | 3.24 | -3922.00% | — | -460.00% | -43.33% | -3.27 | -752.56% | 0.00% | 0.00% | 150.03% | 1.69 | 2.31 | — | 1.75 |
About Neonc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
- CEO
- Amir Farrokh Heshmatpour
- Employees
- 8
- Beta
- 3.30
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.06) − 1 = — (DCF, example).